Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients

Journal of Pathology

Volumn 231, Issue 1, 2013, Pages 117-129

  Mans, Dorus A ^a,d,e   Vermaat, Joost S ^a   Weijts, Bart G ^b   Van Rooijen, Ellen ^a,c   Van Reeuwijk, Jeroen ^d,e   Boldt, Karsten ^f   Daenen, Laura G M ^a   Van Der Groep, Petra ^a   Rowland, Benjamin D ^a   Jans, Judith J ^a   Roepman, Ronald ^d,e   Voest, Emile E ^a   Van Diest, Paul J ^a   Verhaar, Marianne C ^a   De Bruin, Alain ^b   Giles, Rachel H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c HUBRECHT INSTITUTE   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Biomarker; E2F1; Hypoxia; Renal cell carcinoma; Von Hippel Lindau (VHL)

Indexed keywords

TRANSCRIPTION FACTOR E2F1; VON HIPPEL LINDAU PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENE PRODUCT; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SENESCENCE; TUMOR CELL; TUMOR VOLUME;

EID: 84883881767     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4219     Document Type: Article

References (47)

1. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 2008; 8: 865-873.
2. Hsu T. Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms. Oncogene 2012; 31: 2247-2257.
3. Young AP, Schlisio S, Minamishima YA, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 2008; 10: 361-369.
4. Dimri GP, Itahana K, Acosta M, et al. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 2000; 20: 273-285.
5. Ohtani K, Iwanaga R, Nakamura M, et al. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene 1999; 18: 2299-2309.
6. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer. Eur J Cancer 2005; 41: 2403-2414.
7. van Rooijen E, Voest EE, Logister I, et al. von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxiadriven angiogenesis and vascular retinopathies in zebrafish. Dis Model Mech 2010; 3: 343-353.
8. van Rooijen E, Voest EE, Logister I, et al. Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia. Blood 2009; 113: 6449-6460.
9. Lolkema MP, Mans DA, Snijckers CM, et al. The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2. FEBS Lett 2007; 581: 4571-4576.
10. Krieg M, Haas R, Brauch H, et al. Up-regulation of hypoxiainducible factors HIF-1a and HIF-2a under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000; 19: 5435-5443.
11. Sowter HM, Raval RR, Moore JW, et al. Predominant role of hypoxia-inducible transcription factor (Hif)-1a versus Hif-2a in regulation of the transcriptional response to hypoxia. Cancer Res 2003; 63: 6130-6134.
12. Giles RH, Lolkema MP, Snijckers CM, et al. Interplay between VHL/HIF1a and Wnt/β-catenin pathways during colorectal tumorigenesis. Oncogene 2006; 25: 3065-3070.
13. Araki K, Nakajima Y, Eto K, et al. Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter. Oncogene 2003; 22: 7632-7641.
14. Li J, Ran C, Li E, et al. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev Cell 2008; 14: 62-75.
15. Coene KL, Mans DA, Boldt K, et al. The ciliopathy-associated protein homologs RPGRIP1 and RPGRIP1L are linked to cilium integrity through interaction with Nek4 serine/threonine kinase. Hum Mol Genet 2011; 20: 3592-3605.
16. Boldt K, Mans DA, Won J, et al. Disruption of intraflagellar protein transport in photoreceptor cilia causes Leber congenital amaurosis in humans and mice. J Clin Invest 2011; 121: 2169-2180.
17. Kroeze SG, Vermaat JS, van Brussel A, et al. Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. Eur J Cancer 2010; 46: 3375-3382.
18. van Rooijen E, Santhakumar K, Logister I, et al. A zebrafish model for VHL and hypoxia signaling. Methods Cell Biol 2011; 105: 163-190.
19. Ma Y, Croxton R, Moorer RL, Jr., et al. Identification of novel E2F1-regulated genes by microarray. Arch Biochem Biophys 2002; 399: 212-224.
20. Salceda S, Caro J. Hypoxia-inducible factor 1a (HIF-1a) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redoxinduced changes. J Biol Chem 1997; 272: 22642-22647.
21. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 1999; 399: 271-275.
22. O'Connor DJ, Lu X. Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb. Oncogene 2000; 19: 2369-2376.
23. Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998; 95: 11661-11666.
24. Schoenfeld A, Davidowitz EJ, Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1998; 95: 8817-8822.
25. Eng C, Crossey PA, Mulligan LM, et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 1995; 32: 934-937.
26. Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999; 284: 657-661.
27. Tsuchiya H, Iseda T, Hino O. Identification of a novel protein (VBP- 1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res 1996; 56: 2881-2885.
28. Lai Y, Song M, Hakala K, et al. Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res 2011; 10: 5175-5182.
29. Xu L, Hu J, Zhao Y, et al. PDCD5 interacts with p53 and functions as a positive regulator in the p53 pathway. Apoptosis 2012.
30. Zhang Z, Wang H, Li M, et al. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005; 24: 7238-7247.
31. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004.
32. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat 2010; 31: 521-537.
33. Evangelou K, Kotsinas A, Mariolis-Sapsakos T, et al.. E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol 2008; 61: 601-605.
34. Bishop T, Lau KW, Epstein AC, et al. Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol 2004; 2: e289.
35. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16 . Int J Cancer 2012; 130: 1715-1725.
36. Turowska O, Nauman A, Pietrzak M, et al. Overexpression of E2F1 in clear cell renal cell carcinoma: a potential impact of erroneous regulation by thyroid hormone nuclear receptors. Thyroid 2007; 17: 1039-1048.
37. Li CG, Nyman JE, Braithwaite AW, et al. PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein. Oncogene 2011; 30: 4824-4834.
38. Yamasaki L, Jacks T, Bronson R, et al. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-548.
39. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008; 123: 395-400.
40. Carnevale J, Palander O, Seifried LA, et al. DNA damage signals through differentially modified E2F1 molecules to induce apoptosis. Mol Cell Biol 2012; 32: 900-912.
41. Pickering MT, Stadler BM, Kowalik TF. miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene 2009; 28: 140-145.
42. Wang C, Hou X, Mohapatra S, et al. Activation of p27Kip1 expression by E2F1. A negative feedback mechanism. J Biol Chem 2005; 280: 12339-12343.
43. Mamillapalli R, Gavrilova N, Mihaylova VT, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF (SKP2). Curr Biol 2001; 11: 263-267.
44. Roe JS, Kim HR, Hwang IY, et al. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Oncogene 2011; 30: 3127-3138.
45. Migita T, Oda Y, Naito S, et al. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002; 94: 973-979.
46. Dahinden C, Ingold B, Wild P, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010; 16: 88-98.
47. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008; 13: 11-22.